1Embio

1Embio is a South Korean biotechnology company focused on developing next-generation therapeutics using microbial extracellular vesicles (EVs). The company's proprietary EM-Platform enables the discovery and mass production of high-purity EVs derived from beneficial bacteria, which are designed to modulate immune responses and treat various diseases. Their current pipeline includes candidates for atopic dermatitis, inflammatory bowel disease, and oncology, aiming to provide safer and more stable alternatives to live biotherapeutic products. By leveraging the unique signaling properties of microbial vesicles, 1Embio seeks to address significant unmet needs in chronic inflammatory and autoimmune conditions. The company is positioned in the "post-microbiome" space, focusing on the functional components of microbes rather than the organisms themselves.